Symic Appoints Alyssa Panitch, Ph.D., as Chair of Scientific Advisory Board

SAN FRANCISCO, June 1, 2016 /PRNewswire/ -- Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Alyssa Panitch, Ph.D., one of the founders of the company and an inventor of Symic's technology, has been appointed to chair the company's Scientific Advisory Board.

"Professor Panitch has played an integral role in the company's growth from the beginning as co-founder and as a member of the scientific advisory board," said Ken Horne, Chief Executive Officer of Symic. "Particularly as we broaden our pipeline with additional research programs there is no one more qualified to fill this newly created leadership position."

Dr. Panitch has over 20 years of experience in biopolymer and biomaterials research, focusing on the design of biomimetic materials for applications in drug delivery and regenerative medicine. Dr. Panitch has co-founded three biotechnology companies based on this research. Currently Professor in Biomedical Engineering and Vice Provost for Faculty Affairs at Purdue University, Dr. Panitch will join the department of Biomedical Engineering at the University of California, Davis, as Chair in June 2016. Dr. Panitch is a Fellow of the American Institute for Medical and Biological Engineering, the Biomedical Engineering Society and the National Academy of Inventors. Dr. Panitch received degrees in both Biochemistry and Chemical Engineering from Smith College and the University of Massachusetts, Amherst, a Ph.D. in Polymer Science and Engineering from the University of Massachusetts at Amherst, and conducted postdoctoral research at the Swiss Federal Institute of Technology (ETH Zurich) and the University of Zurich.

About Symic

Symic is a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissue. The ECM plays a critical role in a wide variety of processes involved in acute and chronic indications. Symic's proprietary compounds function like proteoglycans, which are naturally occurring macromolecules that play important structural and regulatory functions in the ECM. Symic currently has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.

For additional information please visit the company's website at http://www.symic.bio, LinkedIn page www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.

Media Contacts

David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]

SOURCE Symic

Related Links

http://www.symic.bio